Using Chemical Modification to Enhance siRNA Performance

Handbook of RNA Biochemistry: Second, Completely Revised and Enlarged Edition

Volumn 2-2, Issue , 2014, Pages 1243-1278

  Bramsen, Jesper B ^a   Grünweller, Arnold ^b   Hartmann, Roland K ^b   Kjems, Jørgen ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

fluorarabino (FANA); fluoro ( F); inverted abasic end cap; O methyl ( OMe); thio ( S); 19 bp siRNA; 27 bp siRNA; AiRNA; Alteration of ribose backbone; Altritol nucleic acid (ANA); Antisense strand (AS); AsiRNA; Backbone modifications; Base modifications; Bioavailability; Biostability; Blunt fork siRNA; Blunt siRNA; Boranophosphate (PB); Bulge siRNA; Cellular delivery of siRNA; Chemical modification of siRNAs; Cyclohexene nucleic acid (CeNA); Dicer independent short shRNA; Different siRNA designs and architectures; DNA; Dumbbell siRNA; Ethylene bridged nucleic acid (ENA); Gene knockdown (KD); Guide strand; Guide strand selection by RISC; Hexitol nucleic acid; Locked nucleic acid (LNA); Long shRNA; MiRNA like effects; Modification of seed; Nuclease resistance of siRNAs; Off target effect (OTE); Passenger strand; Phosphonoacetate (PAc); Phosphorothioate (PS); Seed modification; Seed of guide strand; Sense strand (SS); Silencing duration; SiRNA activity; SiRNA conjugation; SiRNA helix stability asymmetry; SiRNA immunogenicity; SiRNA potency; SiRNA ribose modifications; SisiRNA; Small interfering RNAs (siRNAs); Ss siRNA; Unlocked nucleic acid (UNA)

Indexed keywords

EID: 84977630630     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527647064.ch56     Document Type: Chapter

References (201)

1. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
2. Elbashir, S.M., Martinez, J., Patkaniowska, A., Lendeckel, W., and Tuschl, T. (2001) Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J., 20, 6877-6888.
3. Kim, D.H., Behlke, M.A., Rose, S.D., Chang, M.S., Choi, S., and Rossi, J.J. (2005) Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol., 23, 222-226.
4. Amarzguioui, M., Lundberg, P., Cantin, E., Hagstrom, J., Behlke, M.A., and Rossi, J.J. (2006) Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat. Protoc., 1, 508-517.
5. Hefner, E., Clark, K., Whitman, C., Behlke, M.A., Rose, S.D., Peek, A.S., and Rubio, T. (2008) Increased potency and longevity of gene silencing using validated Dicer substrates. J. Biomol. Technol., 19, 231-237.
6. Collingwood, M.A., Rose, S.D., Huang, L., Hillier, C., Amarzguioui, M., Wiiger, M.T., Soifer, H.S., Rossi, J.J., and Behlke, M.A. (2008) Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides, 18, 187-200.
7. Siolas, D., Lerner, C., Burchard, J., Ge, W., Linsley, P.S., Paddison, P.J., Hannon, G.J., and Cleary, M.A. (2005) Synthetic shRNAs as potent RNAi triggers. Nat. Biotechnol., 23, 227-231.
8. Tanudji, M., Machalek, D., Arndt, G.M., and Rivory, L. (2010) Competition between siRNA duplexes:impact of RNA-induced silencing complex loading efficiency and comparison between conventional-21 bp and Dicer-substrate siRNAs. Oligonucleotides, 20, 27-32.
9. Reynolds, A., Anderson, E.M., Vermeulen, A., Fedorov, Y., Robinson, K., Leake, D., Karpilow, J., Marshall, W.S., and Khvorova, A. (2006) Induction of the interferon response by siRNA is cell type-and duplex length-dependent. RNA, 12, 988-993.
10. Rose, S.D., Kim, D.H., Amarzguioui, M., Heidel, J.D., Collingwood, M.A., Davis, M.E., Rossi, J.J., and Behlke, M.A. (2005) Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res., 33, 4140-4156.
11. Ge, Q., Ilves, H., Dallas, A., Kumar, P., Shorenstein, J., Kazakov, S.A., and Johnston, B.H. (2010) Minimal-length short hairpin RNAs: The relationship of structure and RNAi activity. RNA, 16, 106-117.
12. Ge, Q., Dallas, A., Ilves, H., Shorenstein, J., Behlke, M.A., and Johnston, B.H. (2009) Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA, 16, 118-130.
13. Chu, C.Y. and Rana, T.M. (2008) Potent RNAi by short RNA triggers. RNA, 14, 1714-1719.
14. Prakash, T.P., Allerson, C.R., Dande, P., Vickers, T.A., Sioufi, N., Jarres, R., Baker, B.F., Swayze, E.E., Griffey, R.H., and Bhat, B. (2005) Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem., 48, 4247-4253.
15. Czauderna, F., Fechtner, M., Dames, S., Aygün, H., Klippel, A., Pronk, G.J., Giese, K., and Kaufmann, J. (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res., 31, 2705-2716.
16. Hohjoh, H. (2002) RNA interference (RNA(i)) induction with various types of synthetic oligonucleotide duplexes in cultured human cells. FEBS Lett., 521, 195-199.
17. Hohjoh, H. (2004) Enhancement of RNAi activity by improved siRNA duplexes. FEBS Lett., 557, 193-198.
18. Holen, T., Amarzguioui, M., Babaie, E., and Prydz, H. (2003) Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway. Nucleic Acids Res., 31, 2401-2407.
19. Martinez, J., Patkaniowska, A., Urlaub, H., Lührmann, R., and Tuschl, T. (2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell, 110, 563-574.
20. Hall, A.H., Wan, J., Spesock, A., Sergueeva, Z., Shaw, B.R., and Alexander, K.A. (2006) High potency silencing by single-stranded boranophosphate siRNA. Nucleic Acids Res., 34, 2773-2781.
21. Abe, N., Abe, H., and Ito, Y. (2007) Dumbbell-shaped nanocircular RNAs for RNA interference. J. Am. Chem. Soc., 129, 15108-15109.
22. Sun, X., Rogoff, H.A., and Li, C.J. (2008) Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat. Biotechnol., 26, 1379-1382.
23. Chang, C.I., Yoo, J.W., Hong, S.W., Lee, S.E., Kang, H.S., Sun, X., Rogoff, H.A., Ban, C., Kim, S., Li, C.J. et al. (2009) Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol. Ther., 17, 725-732.
24. Dua, P., Yoo, J.W., Kim, S., and Lee, D.K. (2011) Modified siRNA structure with a single nucleotide bulge overcomes conventional siRNA-mediated off-target silencing. Mol. Ther., 19, 1676-1687.
25. Sano, M., Sierant, M., Miyagishi, M., Nakanishi, M., Takagi, Y., and Sutou, S. (2008) Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection. Nucleic Acids Res., 36, 5812-5821.
26. Bramsen, J.B., Laursen, M.B., Damgaard, C.K., Lena, S.W., Babu, B.R., Wengel, J., and Kjems, J. (2007) Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res., 35, 5886-5897.
27. Bramsen, J.B., Laursen, M.B., Nielsen, A.F., Hansen, T.B., Bus, C., Langkjær, N., Babu, B.R., Højland, T., Abramov, M., Van Aerschot, A. et al. (2009) A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res., 37, 2867-2881.
28. Wang, Y., Sheng, G., Juranek, S., Tuschl, T., and Patel, D.J. (2008) Structure of the guide-strand-containing argonaute silencing complex. Nature, 456, 209-213.
29. Nykanen, A., Haley, B., and Zamore, P.D. (2001) ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell, 107, 309-321.
30. Lima, W.F., Wu, H., Nichols, J.G., Sun, H., Murray, H.M., and Crooke, S.T. (2009) Binding and cleavage specificities of human Argonaute2. J. Biol. Chem., 284, 26017-26028.
31. Meister, G. and Tuschl, T. (2004) Mechanisms of gene silencing by double-stranded RNA. Nature, 431, 343-349.
32. Wang, Y., Juranek, S., Li, H., Sheng, G., Wardle, G.S., Tuschl, T., and Patel, D.J. (2009) Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes. Nature, 461, 754-761.
33. Ma, J.B., Ye, K., and Patel, D.J. (2004) Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature, 429, 318-322.
34. Tomari, Y. and Zamore, P.D. (2005) Perspective: machines for RNAi. Genes Dev., 19, 517-529.
35. Khvorova, A., Reynolds, A., and Jayasena, S.D. (2003) Functional siRNAs and miRNAs exhibit strand bias. Cell, 115, 209-216.
36. Walton, S.P., Wu, M., Gredell, J.A., and Chan, C. (2010) Designing highly active siRNAs for therapeutic applications. FEBS J., 277, 4806-4813.
37. Aboul-Fadl, T. (2005) Antisense oligonucleotides: the state of the art. Curr. Med. Chem., 12, 2193-2214.
38. Eckstein, F. (2002) Developments in RNA chemistry, a personal view. Biochimie, 84, 841-848.
39. Harborth, J., Elbashir, S.M., Vandenburgh, K., Manninga, H., Scaringe, S.A., Weber, K., and Tuschl, T. (2003) Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev., 13, 83-105.
40. Amarzguioui, M., Holen, T., Babaie, E., and Prydz, H. (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res., 31, 589-595.
41. Chiu, Y.L. and Rana, T.M. (2003) siRNA function in RNAi: a chemical modification analysis. RNA, 9, 1034-1048.
42. Choung, S., Kim, Y.J., Kim, S., Park, H.O., and Choi, Y.C. (2006) Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun., 342, 919-927.
43. Braasch, D.A., Jensen, S., Liu, Y., Kaur, K., Arar, K., White, M.A., and Corey, D.R. (2003) RNA interference in mammalian cells by chemically-modified RNA. Biochemistry, 42, 7967-7975.
44. Grünweller, A., Wyszko, E., Bieber, B., Jahnel, R., Erdmann, V.A., and Kurreck, J. (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res., 31, 3185-3193.
45. Hall, A.H., Wan, J., Shaughnessy, E.E., Ramsay Shaw, B., and Alexander, K.A. (2004) RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res., 32, 5991-6000.
46. Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H.F., Berger, U. et al. (2008) LNA-mediated microRNA silencing in non-human primates. Nature, 452, 896-899.
47. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J. et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 432, 173-178.
48. Chen, Q., Butler, D., Querbes, W., Pandey, R.K., Ge, P., Maier, M.A., Zhang, L., Rajeev, K.G., Nechev, L., Kotelianski, V. et al. (2010) Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J. Controlled Release, 144, 227-232.
49. Nishina, K., Unno, T., Uno, Y., Kubodera, T., Kanouchi, T., Mizusawa, H., and Yokota, T. (2008) Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther., 16, 734-740.
50. Layzer, J.M., McCaffrey, A.P., Tanner, A.K., Huang, Z., Kay, M.A., and Sullenger, B.A. (2004) In vivo activity of nuclease-resistant siRNAs. RNA, 10, 766-771.
51. Mook, O.R., Baas, F., de Wissel, M.B., and Fluiter, K. (2007) Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol. Cancer Ther., 6, 833-843.
52. Laursen, M.B., Pakula, M.M., Gao, S., Fluiter, K., Mook, O.R., Baas, F., Langklær, N., Wengel, S.L., Wengel, J., Kjems, J. et al. (2010) Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol. BioSyst., 6, 862-870.
53. Bramsen, J.B., Pakula, M.M., Hansen, T.B., Bus, C., Langkjær, N., Odadzic, D., Smicius, R., Wengel, S.L., Chattopadhyaya, J., Engels, J.W. et al. (2010) A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res., 38, 5761-5773.
54. Morrissey, D.V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J.A., Dickinson, B., McSwiggen, J.A., Vargeese, C., Bowman, K., Shaffer, C.S. et al. (2005) Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology, 41, 1349-1356.
55. Morrissey, D.V., Lockridge, J.A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V. et al. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol., 23, 1002-1007.
56. Manoharan, M., Akinc, A., Pandey, R.K., Qin, J., Hadwiger, P., John, M., Mills, K., Charisse, K., Maier, M.A., Nechev, L. et al. (2011) Unique gene-silencing and structural properties of 2′-fluoro-modified siRNAs. Angew. Chem. Int. Ed. Engl., 50, 2284-2288.
57. Li, P., Sergueeva, Z.A., Dobrikov, M., and Shaw, B.R. (2007) Nucleoside and oligonucleoside boranophosphates:chemistry and properties. Chem. Rev., 107, 4746-4796.
58. Sheehan, D., Lunstad, B., Yamada, C.M., Stell, B.G., Caruthers, M.H., and Dellinger, D.J. (2003) Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides. Nucleic Acids Res., 31, 4109-4118.
59. Yamada, C.M., Dellinger, D.J., and Caruthers, M.H. (2007) Synthesis and biological activity of phosphonocarboxylate DNA. Nucleosides Nucleotides Nucleic Acids, 26, 539-546.
60. Iwase, R., Toyama, T., and Nishimori, K. (2007) Solid-phase synthesis of modified RNAs containing amide-linked oligoribonucleosides at their 3′-end and their application to siRNA. Nucleosides Nucleotides Nucleic Acids, 26, 1451-1454.
61. Prakash, T.P., Kraynack, B., Baker, B.F., Swayze, E.E., and Bhat, B. (2006) RNA interference by 2′,5′-linked nucleic acid duplexes in mammalian cells. Bioorg. Med. Chem. Lett., 16, 3238-3240.
62. Freier, S.M. and Altmann, K.H. (1997) The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res., 25, 4429-4443.
63. Jackson, A.L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J.M., Lim, L., Karpilow, J., Nichols, K. et al. (2006) Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA, 12, 1197-1205.
64. Kraynack, B.A. and Baker, B.F. (2006) Small interfering RNAs containing full 2′-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. RNA, 12, 163-176.
65. Allerson, C.R., Sioufi, N., Jarres, R., Prakash, T.P., Naik, N., Berdeja, A., Wanders, L., Griffey, R.H., Swayze, E.E., and Bhat, B. (2005) Fully 2 -modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem., 48, 901-904.
66. Capodici, J., Kariko, K., and Weissman, D. (2002) Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J. Immunol., 169, 5196-5201.
67. Blidner, R.A., Hammer, R.P., Lopez, M.J., Robinson, S.O., and Monroe, W.T. (2007) Fully 2 -deoxy-2 -fluoro substituted nucleic acids induce RNA interference in mammalian cell culture. Chem. Biol. Drug Des., 70, 113-122.
68. Watts, J.K., Choubdar, N., Sadalapure, K., Robert, F., Wahba, A.S., Pelletier, J., Pinto, B.M., and Damha, M.J. (2007) 2 -fluoro-4 -thioarabino-modified oligonucleotides: conformational switches linked to siRNA activity. Nucleic Acids Res., 35, 1441-1451.
69. Deleavey, G.F., Watts, J.K., Alain, T., Robert, F., Kalota, A., Aishwarya, V., Pelletier, J., Gewirtz, A.M., Sonenberg, N., and Damha, M.J. (2010) Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucleic Acids Res., 38, 4547-4557.
70. Strapps, W.R., Pickering, V., Muiru, G.T., Rice, J., Orsborn, S., Polisky, B.A., Sachs, A., and Bartz, S.R. (2010) The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing. Nucleic Acids Res., 38, 4788-4797.
71. Pirollo, K.F., Rait, A., Zhou, Q., Hwang, S.H., Dagata, J.A., Zon, G., Hogrefe, R.I., Palchik, G., and Chang, E.H. (2007) Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res., 67, 2938-2943.
72. Hogrefe, R.I., Lebedev, A.V., Zon, G., Pirollo, K.F., Rait, A., Zhou, Q., Yu, W., and Chang, E.H. (2006) Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids, 25, 889-907.
73. Parrish, S., Fleenor, J., Xu, S., Mello, C., and Fire, A. (2000) Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol. Cell, 6, 1077-1087.
74. Ui-Tei, K., Naito, Y., Zenno, S., Nishi, K., Yamato, K., Takahashi, F., Juni, A., and Saigo, K. (2008) Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res., 36, 2136-2151.
75. Odadzic, D., Bramsen, J.B., Smicius, R., Bus, C., Kjems, J., and Engels, J.W. (2008) Synthesis of 2 -O-modified adenosine building blocks and application for RNA interference. Bioorg. Med. Chem., 16, 518-529.
76. Wengel, J., Petersen, M., Nielsen, K.E., Jensen, G.A., Håkansson, A.E., Kumar, R., Sørensen, M.D., Rajwanshi, V.K., Bryld, T., and Jacobsen, J.P. (2001) LNA (locked nucleic acid) and the diastereoisomeric alpha-L-LNA: conformational tuning and high-affinity recognition of DNA/RNA targets. Nucleosides Nucleotides Nucleic Acids, 20, 389-396.
77. Srivastava, P., Barman, J., Pathmasiri, W., Plashkevych, O., Wenska, M., and Chattopadhyaya, J. (2007) Fiveand six-membered conformationally locked 2 ,4 -carbocyclic ribo-thymidines:synthesis, structure, and biochemical studies. J. Am. Chem. Soc., 129, 8362-8379.
78. Hamada, M., Ohtsuka, T., Kawaida, R., Koizumi, M., Morita, K., Furukawa, H., Imanishi, T., Miyagishi, M., and Taira, K. (2002) Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3 -ends of siRNAs. Antisense Nucleic Acid Drug Dev., 12, 301-309.
79. Pradeepkumar, P.I., Amirkhanov, N.V., and Chattopadhyaya, J. (2003) Antisense oligonuclotides with oxetane-constrained cytidine enhance heteroduplex stability, and elicit satisfactory RNase H response as well as showing improved resistance to both exo and endonucleases. Org. Biomol. Chem., 1, 81-92.
80. Kurreck, J., Wyszko, E., Gillen, C., and Erdmann, V.A. (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res., 30, 1911-1918.
81. Fluiter, K., ten Asbroek, A.L., de Wissel, M.B., Jakobs, M.E., Wissenbach, M., Olsson, H., Olsen, O., Oerum, H., and Baas, F. (2003) In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res., 31, 953-962.
82. Elmén, J., Thonberg, H., Ljungberg, K., Frieden, M., Westergaard, M., Xu, Y., Wahren, B., Liang, Z., Ørum, H., Koch, T., and Wahlestedt, C. (2005) Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res., 33, 439-447.
83. Petersen, M. and Wengel, J. (2003) LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol., 21, 74-81.
84. Glud, S.Z., Bramsen, J.B., Dagnaes-Hansen, F., Wengel, J., Howard, K.A., Nyengaard, J.R., and Kjems, J. (2009) Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. Oligonucleotides, 19, 163-168.
85. Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A. et al. (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med., 11, 263-270.
86. Dowler, T., Bergeron, D., Tedeschi, A.L., Paquet, L., Ferrari, N., and Damha, M.J. (2006) Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-beta-D-arabinonucleic acid (FANA). Nucleic Acids Res., 34, 1669-1675.
87. Fisher, M., Abramov, M., Van Aerschot, A., Rozenski, J., Dixit, V., Juliano, R.L., and Herdewijn, P. (2009) Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf. Eur. J. Pharmacol., 606, 38-44.
88. Fisher, M., Abramov, M., VanAerschot, A., Xu, D., Juliano, R.L., and Herdewijn, P. (2007) Inhibition of MDR1 expression with altritol-modified siRNAs. Nucleic Acids Res., 35, 1064-1074.
89. Nauwelaerts, K., Fisher, M., Froeyen, M., Lescrinier, E., Aerschot, A.V., Xu, D., DeLong, R., Kang, H., Juliano, R.L., and Herdewijn, P. (2007) Structural characterization and biological evaluation of small interfering RNAs containing cyclohexenyl nucleosides. J. Am. Chem. Soc., 129, 9340-9348.
90. Langkjær, N., Pasternak, A., and Wengel, J. (2009) UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg. Med. Chem., 17, 5420-5425.
91. Kenski, D.M., Cooper, A.J., Li, J.J., Willingham, A.T., Haringsma, H.J., Young, T.A., Kuklin, N.A., Jones, J.J., Cancilla, M.T., McMasters, D.R. et al. (2009) Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5′-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Res., 38, 660-671.
92. Dande, P., Prakash, T.P., Sioufi, N., Gaus, H., Jarres, R., Berdeja, A., Swayze, E.E., Griffey, R.H., and Bhat, B. (2006) Improving RNA interference in mammalian cells by 4′-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2′-O-alkyl modifications. J. Med. Chem., 49, 1624-1634.
93. Hoshika, S., Minakawa, N., Kamiya, H., Harashima, H., and Matsuda, A. (2005) RNA interference induced by siRNAs modified with 4′-thioribonucleosides in cultured mammalian cells. FEBS Lett., 579, 3115-3118.
94. Hoshika, S., Minakawa, N., Shionoya, A., Imada, K., Ogawa, N., and Matsuda, A. (2007) Study of modification pattern-RNAi activity relationships by using siRNAs modified with 4′-thioribonucleosides. ChemBioChem, 8, 2133-2138.
95. Takahashi, M., Minakawa, N., and Matsuda, A. (2009) Synthesis and characterization of 2′-modified-4′-thioRNA:a comprehensive comparison of nuclease stability. Nucleic Acids Res., 37, 1353-1362.
96. Sipa, K., Sochacka, E., Kazmierczak-Baranska, J., Maszewska, M., Janicka, M., Nowak, G., and Nawrot, B. (2007) Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. RNA, 13, 1301-1316.
97. Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.K., Schlee, M. et al. (2006) 5′-Triphosphate RNA is the ligand for RIG-I. Science, 314, 994-997.
98. Li, Z.Y., Mao, H., Kallick, D.A., and Gorenstein, D.G. (2005) The effects of thiophosphate substitutions on native siRNA gene silencing. Biochem. Biophys. Res. Commun., 329, 1026-1030.
99. Lingel, A., Simon, B., Izaurralde, E., and Sattler, M. (2004) Nucleic acid 3′-end recognition by the Argonaute2 PAZ domain. Nat. Struct. Mol. Biol., 11, 576-577.
100. Chen, P.Y., Weinmann, L., Gaidatzis, D., Pei, Y., Zavolan, M., Tuschl, T., and Meister, G. (2008) Strand-specific 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA, 14, 263-274.
101. Koller, E., Propp, S., Murray, H., Lima, W., Bhat, B., Prakash, T.P., Allerson, C.R., Swayze, E.E., Marcusson, E.G., and Dean, N.M. (2006) Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res., 34, 4467-4476.
102. Tsui, N.B., Ng, E.K., and Lo, Y.M. (2002) Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin. Chem., 48, 1647-1653.
103. Lai, J.C., Tan, W., Benimetskaya, L., Miller, P., Colombini, M., and Stein, C.A. (2006) A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Proc. Natl. Acad. Sci. U.S.A., 103, 7494-7499.
104. Miner, P.B. Jr., Wedel, M.K., Xia, S., and Baker, B.F. (2006) Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment. Pharmacol. Ther., 23, 1403-1413.
105. Bertrand, J.R., Pottier, M., Vekris, A., Opolon, P., Maksimenko, A., and Malvy, C. (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun., 296, 1000-1004.
106. Chiu, Y.L. and Rana, T.M. (2002) RNAi in human cells: basic structural and functional features of small interfering RNA. Mol. Cell, 10, 549-561.
107. Kennedy, S., Wang, D., and Ruvkun, G. (2004) A conserved siRNA-degrading RNase negatively regulates RNA interference in C. elegans. Nature, 427, 645-649.
108. Takabatake, Y., Isaka, Y., Mizui, M., Kawachi, H., Takahara, S., and Imai, E. (2007) Chemically modified siRNA prolonged RNA interference in renal disease. Biochem. Biophys. Res. Commun., 363, 432-437.
109. Haupenthal, J., Baehr, C., Zeuzem, S., and Piiper, A. (2007) RNAse A-like enzymes in serum inhibit the anti-neoplastic activity of siRNA targeting polo-like kinase 1. Int. J. Cancer, 121, 206-210.
110. Haupenthal, J., Baehr, C., Kiermayer, S., Zeuzem, S., and Piiper, A. (2006) Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem. Pharmacol., 71, 702-710.
111. Hickerson, R.P., Vlassov, A.V., Wang, Q., Leake, D., Ilves, H., Gonzalez-Gonzalez, E., Contag, C.H., Johnston, B.H., and Kaspar, R.L. (2008) Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides, 18, 345-354.
112. Tourriere, H., Chebli, K., and Tazi, J. (2002) mRNA degradation machines in eukaryotic cells. Biochimie, 84, 821-837.
113. Sorrentino, S. (1998) Human extracellular ribonucleases: multiplicity, molecular diversity and catalytic properties of the major RNase types. Cell. Mol. Life Sci., 54, 785-794.
114. Probst, J., Brechtel, S., Scheel, B., Hoerr, I., Jung, G., Rammensee, H.G., and Pascolo, S. (2006) Characterization of the ribonuclease activity on the skin surface. Genet Vaccines Ther., 4, 4.
115. Zou, Y., Tiller, P., Chen, I.W., Beverly, M., and Hochman, J. (2008) Metabolite identification of small interfering RNA duplex by high-resolution accurate mass spectrometry. Rapid Commun. Mass Spectrom., 22, 1871-1881.
116. Usher, D.A. (1969) On the mechanism of ribonuclease action. Proc. Natl. Acad. Sci. U.S.A., 62, 661-667.
117. Eder, P.S., DeVine, R.J., Dagle, J.M., and Walder, J.A. (1991) Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res. Dev., 1, 141-151.
118. Zimmermann, T.S., Lee, A.C., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M.N., Harborth, J., Heyes, J.A., Jeffs, L.B., John, M. et al. (2006) RNAi-mediated gene silencing in non-human primates. Nature, 441, 111-114.
119. Volkov, A.A., Kruglova, N.S., Meschaninova, M.I., Venyaminova, A.G., Zenkova, M.A., Vlassov, V.V., and Chernolovskaya, E.L. (2009) Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. Oligonucleotides, 19, 191-202.
120. Turner, J.J., Jones, S.W., Moschos, S.A., Lindsay, M.A., and Gait, M.J. (2007) MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol. Biosyst., 3, 43-50.
121. Qiu, L., Moreira, A., Kaplan, G., Levitz, R., Wang, J.Y., Xu, C., and Drlica, K. (1998) Degradation of hammerhead ribozymes by human ribonucleases. Mol. Gen. Genet., 258, 352-362.
122. Libonati, M. and Sorrentino, S. (1992) Revisiting the action of bovine ribonuclease A and pancreatic-type ribonucleases on double-stranded RNA. Mol. Cell. Biochem., 117, 139-151.
123. Hoerter, J.A. and Walter, N.G. (2007) Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. RNA, 13, 1887-1893.
124. Bartlett, D.W. and Davis, M.E. (2007) Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol. Bioeng., 97, 909-921.
125. Life Technologies Ambion®. Technical Resources, RNAi/siRNA, Duration of siRNA induced silencing: your questions answered. TechNotes (online) 15.
126. Song, E., Lee, S.K., Dykxhoorn, D.M., Novina, C., Zhang, D., Crawford, K., Cerny, J., Sharp, P.A., Lieberman, J., Manjunath, N., and Shankar, P. (2003) Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J. Virol., 77, 7174-7181.
127. Raemdonck, K., Remaut, K., Lucas, B., Sanders, N.N., Demeester, J., and De Smedt, S.C. (2006) In situ analysis of single-stranded and duplex siRNA integrity in living cells. Biochemistry, 45, 10614-10623.
128. Yoo, J.W., Kim, S., and Lee, D.K. (2008) Competition potency of siRNA is specified by the 5′-half sequence of the guide strand. Biochem. Biophys. Res. Commun., 367, 78-83.
129. Sioud, M. (2009) Deciphering the code of innate immunity recognition of siRNAs. Methods Mol. Biol., 487, 41-59.
130. Meurs, E., Chong, K., Galabru, J., Thomas, N.S., Kerr, I.M., Williams, B.R., and Hovanessian, A.G. (1990) Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell, 62, 379-390.
131. Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., and Fujita, T. (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol., 5, 730-737.
132. Marques, J.T., Devosse, T., Wang, D., Zamanian-Daryoush, M., Serbinowski, P., Hartmann, R., Fujita, T., Behlke, M.A., and Williams, B.R. (2006) A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat. Biotechnol., 24, 559-565.
133. Kang, D.C., Gopalkrishnan, R.V., Wu, Q., Jankowsky, E., Pyle, A.M., and Fisher, P.B. (2002) mda-5:An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl. Acad. Sci. U.S.A., 99, 637-642.
134. Puthenveetil, S., Whitby, L., Ren, J., Kelnar, K., Krebs, J.F., and Beal, P.A. (2006) Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucleic Acids Res., 34, 4900-4911.
135. Kim, D.H., Longo, M., Han, Y., Lundberg, P., Cantin, E., and Rossi, J.J. (2004) Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol., 22, 321-325.
136. Kariko, K., Bhuyan, P., Capodici, J., Ni, H., Lubinski, J., Friedman, H., and Weissman, D. (2004) Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3. Cells Tissues Organs, 177, 132-138.
137. Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., and Bauer, S. (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science, 303, 1526-1529.
138. Gantier, M.P., Tong, S., Behlke, M.A., Xu, D., Phipps, S., Foster, P.S., and Williams, B.R. (2008) TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J. Immunol., 180, 2117-2124.
139. Muzio, M., Bosisio, D., Polentarutti, N., D'amico, G., Stoppacciaro, A., Mancinelli, R., van't Veer, C., Penton-Rol, G., Ruco, L.P., Allavena, P., and Mantovani, A. (2000) Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: Selective expression of TLR3 in dendritic cells. J. Immunol., 164, 5998-6004.
140. Kleinman, M.E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J.Z., Albuquerque, R.J.C., Yamasaki, S., Itaya, M., Pan, Y.Z. et al. (2008) Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature, 452, 591-U591.
141. Kariko, K., Bhuyan, P., Capodici, J., and Weissman, D. (2004) Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol., 172, 6545-6549.
142. Alexopoulou, L., Holt, A.C., Medzhitov, R., and Flavell, R.A. (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature, 413, 732-738.
143. Kleinman, M.E., Kaneko, H., Cho, W.G., Dridi, S., Fowler, B.J., Blandford, A.D., Albuquerque, R.J., Hirano, Y., Terasaki, H., Kondo, M. et al. (2012) Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol. Ther., 20, 101-108.
144. Zarember, K.A. and Godowski, P.J. (2002) Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol., 168, 554-561.
145. Diebold, S.S., Massacrier, C., Akira, S., Paturel, C., Morel, Y., and Reis e Sousa, C. (2006) Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur. J. Immunol., 36, 3256-3267.
146. Diebold, S.S., Kaisho, T., Hemmi, H., Akira, S., and Reis e Sousa, C. (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 303, 1529-1531.
147. Judge, A.D., Sood, V., Shaw, J.R., Fang, D., McClintock, K., and MacLachlan, I. (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol., 23, 457-462.
148. Sioud, M. (2005) Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol., 348, 1079-1090.
149. Heidel, J.D., Hu, S., Liu, X.F., Triche, T.J., and Davis, M.E. (2004) Lack of interferon response in animals to naked siRNAs. Nat. Biotechnol., 22, 1579-1582.
150. Kariko, K., Buckstein, M., Ni, H., and Weissman, D. (2005) Suppression of RNA recognition by Toll-like receptors:the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23, 165-175.
151. Cekaite, L., Furset, G., Hovig, E., and Sioud, M. (2007) Gene expression analysis in blood cells in response to unmodified and 2′-modified siRNAs reveals TLR-dependent and independent effects. J. Mol. Biol., 365, 90-108.
152. Judge, A.D., Bola, G., Lee, A.C., and MacLachlan, I. (2006) Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther., 13, 494-505.
153. Hamm, S., Latz, E., Hangel, D., Müller, T., Yu, P., Golenbock, D., Sparwasser, T., Wagner, H., and Bauer, S. (2009) Alternating 2′-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology, 215, 559-569.
154. Robbins, M., Judge, A., Liang, L., McClintock, K., Yaworski, E., and MacLachlan, I. (2007) 2′-O-methyl-modified RNAs act as TLR7 antagonists. Mol. Ther., 15, 1663-1669.
155. Goodchild, A., Nopper, N., King, A., Doan, T., Tanudji, M., Arndt, G.M., Poidinger, M., Rivory, L.P., and Passioura, T. (2009) Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol., 10, 40.
156. Zamanian-Daryoush, M., Marques, J.T., Gantier, M.P., Behlke, M.A., John, M., Rayman, P., Finke, J., and Williams, B.R. (2008) Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J. Interferon Cytokine Res., 28, 221-233.
157. Du, Q., Thonberg, H., Wang, J., Wahlestedt, C., and Liang, Z. (2005) A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res., 33, 1671-1677.
158. Dahlgren, C., Zhang, H.Y., Du, Q., Grahn, M., Norstedt, G., Wahlestedt, C., and Liang, Z. (2008) Analysis of siRNA specificity on targets with double-nucleotide mismatches. Nucleic Acids Res., 36, e53.
159. Jackson, A.L., Bartz, S.R., Schelter, J., Kobayashi, S.V., Burchard, J., Mao, M., Li, B., Cavet, G., and Linsley, P.S. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol., 21, 635-637.
160. Birmingham, A., Anderson, E.M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J. et al. (2006) 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods, 3, 199-204.
161. Lim, L.P., Lau, N.C., Garrett-Engele, P., Grimson, A., Schelter, J.M., Castle, J., Bartel, D.P., Linsley, P.S., and Johnson, J.M. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 433, 769-773.
162. Doench, J.G., Petersen, C.P., and Sharp, P.A. (2003) siRNAs can function as miRNAs. Genes Dev., 17, 438-442.
163. Fedorov, Y., Anderson, E.M., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K., Leake, D., Marshall, W.S., and Khvorova, A. (2006) Off-target effects by siRNA can induce toxic phenotype. RNA, 12, 1188-1196.
164. Lin, X., Ruan, X., Anderson, M.G., McDowell, J.A., Kroeger, P.E., Fesik, S.W., and Shen, Y. (2005) siRNAmediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res., 33, 4527-4535.
165. Doench, J.G. and Sharp, P.A. (2004) Specificity of microRNA target selection in translational repression. Genes Dev., 18, 504-511.
166. Williams, A.E. (2008) Functional aspects of animal microRNAs. Cell. Mol. Life Sci., 65, 545-562.
167. Wu, L., Fan, J., and Belasco, J.G. (2006) MicroRNAs direct rapid deadenylation of mRNA. Proc. Natl. Acad. Sci. U.S.A., 103, 4034-4039.
168. Vaish, N., Chen, F., Seth, S., Fosnaugh, K., Liu, Y., Adami, R., Brown, T., Chen, Y., Harvie, P., Johns, R. et al. (2011) Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res., 39, 1823-1832.
169. Stewart, S.A., Dykxhoorn, D.M., Palliser, D., Mizuno, H., Yu, E.Y., An, D.S., Sabatini, D.M., Chen, I.S., Hahn, W.C., Sharp, P.A. et al. (2003) Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA, 9, 493-501.
170. Laktionov, P.P., Dazard, J.E., Vives, E., Rykova, E.Y., Piette, J., Vlassov, V.V., and Lebleu, B. (1999) Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes. Nucleic Acids Res., 27, 2315-2324.
171. de Diesbach, P., Berens, C., N'Kuli, F., Monsigny, M., Sonveaux, E., Wattiez, R., and Courtoy, P.J. (2000) Identification, purification and partial characterisation of an oligonucleotide receptor in membranes of HepG2 cells. Nucleic Acids Res., 28, 868-874.
172. Lingor, P., Michel, U., Schöll, U., Bähr, M., and Kügler, S. (2004) Transfection of "naked" siRNA results in endosomal uptake and metabolic impairment in cultured neurons. Biochem. Biophys. Res. Commun., 315, 1126-1133.
173. Overhoff, M., Wünsche, W., and Sczakiel, G. (2004) Quantitative detection of siRNA and single-stranded oligonucleotides: relationship between uptake and biological activity of siRNA. Nucleic Acids Res., 32, e170.
174. Davidson, T.J., Harel, S., Arboleda, V.A., Prunell, G.F., Shelanski, M.L., Greene, L.A., and Troy, C.M. (2004) Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J. Neurosci., 24, 10040-10046.
175. Muratovska, A. and Eccles, M.R. (2004) Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett., 558, 63-68.
176. Moschos, S.A., Jones, S.W., Perry, M.M., Williams, A.E., Erjefalt, J.S., Turner, J.J., Barnes, P.J., Sproat, B.S., Gait, M.J., and Lindsay, M.A. (2007) Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug. Chem., 18, 1450-1459.
177. Kim, W.J., Christensen, L.V., Jo, S., Yockman, J.W., Jeong, J.H., Kim, Y.H., and Kim, S.W. (2006) Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol. Ther., 14, 343-350.
178. Chiu, Y.L., Ali, A., Chu, C.Y., Cao, H., and Rana, T.M. (2004) Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol., 11, 1165-1175.
179. Abes, S., Moulton, H., Turner, J., Clair, P., Richard, J.P., Iversen, P., Gait, M.J., and Lebleu, B. (2007) Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides. Biochem. Soc. Trans., 35, 53-55.
180. Bolcato-Bellemin, A.L., Bonnet, M.E., Creusat, G., Erbacher, P., and Behr, J.P. (2007) Sticky overhangs enhance siRNA-mediated gene silencing. Proc. Natl. Acad. Sci. U.S.A., 104, 16050-16055.
181. Lee, S.Y., Huh, M.S., Lee, S., Lee, S.J., Chung, H., Park, J.H., Oh, Y.K., Choi, K., Kim, K., and Kwon, I.C. (2009) Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing. J. Controlled Release, 141, 339-346.
182. Ikeda, Y. and Taira, K. (2006) Ligand-targeted delivery of therapeutic siRNA. Pharm. Res., 23, 1631-1640.
183. Medarova, Z., Pham, W., Farrar, C., Petkova, V., and Moore, A. (2007) In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med., 13, 372-377.
184. Derfus, A.M., Chen, A.A., Min, D.H., Ruoslahti, E., and Bhatia, S.N. (2007) Targeted quantum dot conjugates for siRNA delivery. Bioconjug. Chem., 18, 1391-1396.
185. Oishi, M., Nagasaki, Y., Nishiyama, N., Itaka, K., Takagi, M., Shimamoto, A., Furuichi, Y., and Kataoka, K. (2007) Enhanced growth inhibition of hepatic multicellular tumor spheroids by lactosylated poly(ethylene glycol)-siRNA conjugate formulated in PEGylated polyplexes. ChemMedChem, 2, 1290-1297.
186. Cesarone, G., Edupuganti, O.P., Chen, C.P., and Wickstrom, E. (2007) Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. Bioconjug. Chem., 18, 1831-1840.
187. Xia, C.F., Zhang, Y., Boado, R.J., and Pardridge, W.M. (2007) Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm. Res., 24, 2309-2316.
188. Oishi, M., Nagasaki, Y., Itaka, K., Nishiyama, N., and Kataoka, K. (2005) Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc., 127, 1624-1625.
189. Kim, S.S., Garg, H., Joshi, A., and Manjunath, N. (2009) Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol. Med., 15, 491-500.
190. Gao, S., Dagnaes-Hansen, F., Nielsen, E.J., Wengel, J., Besenbacher, F., Howard, K.A., and Kjems, J. (2009) The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther., 17, 1225-1233.
191. Bartlett, D.W. and Davis, M.E. (2008) Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng., 99, 975-985.
192. Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F., and Aigner, A. (2005) RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther., 12, 461-466.
193. Schiffelers, R.M., Ansari, A., Xu, J., Zhou, Q., Tang, Q., Storm, G., Molema, G., Lu, P.Y., Scaria, P.V., and Woodle, M.C. (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res., 32, e149.
194. Song, E., Zhu, P., Lee, S.K., Chowdhury, D., Kussman, S., Dykxhoorn, D.M., Feng, Y., Palliser, D., Weiner, D.B., Shankar, P. et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol., 23, 709-717.
195. Heidel, J.D., Yu, Z., Liu, J.Y., Rele, S.M., Liang, Y., Zeidan, R.K., Kornbrust, D.J., and Davis, M.E. (2007) Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U.S.A., 104, 5715-5721.
196. Kim, S.H., Mok, H., Jeong, J.H., Kim, S.W., and Park, T.G. (2006) Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug. Chem., 17, 241-244.
197. Shen, J., Samul, R., Silva, R.L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S.F., Zinnen, S., Kossen, K., Fosnaugh, K. et al. (2006) Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther., 13, 225-234.
198. Wolfrum, C., Shi, S., Jayaprakash, K.N., Jayaraman, M., Wang, G., Pandey, R.K., Rajeev, K.G., Nakayama, T., Charrise, K., Ndungo, E.M. et al. (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol., 25, 1149-1157.
199. Bumcrot, D., Manoharan, M., Koteliansky, V., and Sah, D.W. (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol., 2, 711-719.
200. Myers, J.W., Chi, J.T., Gong, D., Schaner, M.E., Brown, P.O., and Ferrell, J.E. (2006) Minimizing off-target effects by using diced siRNAs for RNA interference. J. RNAi Gene Silencing, 2, 181-194.
201. Kittler, R., Surendranath, V., Heninger, A.K., Slabicki, M., Theis, M., Putz, G., Franke, K., Caldarelli, A., Grabner, H., Kozak, K. et al. (2007) Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. Nat. Methods, 4, 337-344.